Medicare's Bold Experiment: Weight-Loss Drugs on the Horizon

The Trump administration is gearing up to introduce a groundbreaking plan aimed at including weight-loss drugs under Medicare and Medicaid coverage, as reported by the Washington Post.

The initiative, which involves voluntary coverage by state Medicaid programs and Medicare Part D, focuses on GLP-1 drugs such as Ozempic, Wegovy, Mounjaro, and Zepbound for effective weight management. Set to launch in April 2026 for Medicaid and January 2027 for Medicare, the program marks a significant step in public health policy.

However, the Centers for Medicare & Medicaid Services have yet to respond to Reuters with comments regarding the forthcoming plan.

(With inputs from agencies.)